Sina Kianersi, PhD, is a research fellow in medicine at Brigham and Women’s Hospital.

Staying Up Late Associated With CVD Risk Through Worse LE8 Scores, With Sina Kianersi, PhD

Individuals with an evening chronotype, or “night owls,” may be at greater risk of 

; however, a significant percentage of contributing factors are modifiable.

During the 14-year trial, participants with a “definitely evening” chronotype – defined as having a late-night bedtime such as 2 a.m. and peak activity later in the day – were associated with a 79% higher prevalence of overall poor Life’s Essential 8 (LE8) scores. By the end of the trial, investigators had recorded 17,584 incident cardiovascular disease events.

“The encouraging part of our findings, however, is that roughly 75% of that difference seemed to be explained by modifiable factors such as sleep, physical activity, smoking, weight, blood pressure, cholesterol, and blood sugar,” Sina Kianersi, PhD, research fellow in medicine at Brigham and Women’s Hospital, told 

Kianersi and colleagues conducted a prospective study using UK Biobank assessment center visits as the baseline. A total of 502,128 patients were initially included in the dataset – of these, 6172 were excluded due to missing chronotype information, 18,292 were excluded due to a history of myocardial infarction (MI) or 

 at baseline, and 154,887 were excluded due to incomplete data on ≥1 lifestyle behaviors or factors among LE8. A total of 322,777 patients were ultimately enrolled and followed up over a duration of 14 years.

Chronotype was self-reported at baseline visit using a single question from the Morningness-Eveningness Questionnaire. This question’s correlation coefficient with the full questionnaire score surpasses 0.72. The LE8 framework is composed of 4 health behaviors – diet, physical activity, nicotine exposure, and sleep health – and 4 health factors – body weight, blood lipids, blood glucose, and blood pressure. Each component has a scoring algorithm from 0 to 100, with higher scores indicating better cardiovascular health. Diet, physical activity, sleep duration, and nicotine exposure were self-reported, while weight, blood lipids, blood glucose, and blood pressure were measured directly.

The mean age of the study population was 57 years (+/- standard deviation [SD] 8). Roughly 58% of participants had a family history of cardiovascular disease. The majority of participants (67%) had an “intermediate” chronotype, with 8% reporting a "definitely evening" chronotype. Compared with the “intermediate” chronotype, those with a “definitely evening” chronotype were younger, were more frequently engaged in shift work (12% vs 9%), more frequently held college degrees (43% vs 37%), and had a lower overall LE8 score (65 vs 68). In a descriptive analysis, “definitely evening” participants had notably poorer scores in 7 of 8 components compared to the “intermediate” participants.

Ultimately, after a median follow-up of 13.8 years (interquartile range [IQR], 1.6), 17,584 incident cardiovascular disease cases (MI = 11,091; stroke = 7214) were documented among all participants. Compared with the “intermediate” chronotype, those with a “definitely evening” chronotype had a 16% higher risk of cardiovascular disease (HR, 1.16; 95% CI, 1.1-1.22), while those reporting “definitely morning” chronotypes were not at an increased risk (HR, 1.03; 95% CI, 0.99-1.07). After adjusting for the 8 LE8 components, associations attenuated; however, no direct effect of evening chronotype on cardiovascular disease was observed, as the natural indirect effect, representing the effect mediated by the overall LE8 score, was 1.11 (95% CI, 1.09-1.13). This indicated that 75% of the association between chronotype and incident cardiovascular disease was mediated through these scores.

Ultimately, although evening chronotype was directly associated with a poorer score in LE8, this renders it reversible through alterations to diet, physical activity, and nicotine exposure, among other factors. Kianersi and colleagues emphasized that chronotype had no direct influence on cardiovascular disease.

“One of the limitations of the study is that we followed the cohort for about 14 years, and the risk is for that specific number of years,” Kianersi said. “The risk might be different for shorter or longer study periods – it might change if we follow participants for a longer time, as we had in our previous studies.”

Editor’s Note: Kianersi reports no relevant disclosures.

American Heart Association. Being a night owl may increase your heart risk. 

. January 28, 2026. Accessed January 29, 2026. 

https://www.eurekalert.org/news-releases/1113759

Kianersi S, Potts KS, Wang H, et al. Chronotype, life’s essential 8, and risk of cardiovascular disease: A prospective cohort study in UK Biobank. Journal of the American Heart Association. Published online January 28, 2026. 

Videos

Kianersi discusses how, although evening chronotype can be associated indirectly with increased CVD risk, this can be mediated via Life’s Essential 8 scores.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Stroke

On the HCPLive stroke page, resources on the topics of medical news and expert insight into CVA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on stroke medicine, and more.

Highlighting Therapeutic Updates for Atopic Dermatitis and Itch, With Lawrence Eichenfield, MD

, the ‘Atopic Dermatitis and Pruritus: Current Concepts and Therapeutics for 2026’ talk was presented, with 3 speakers highlighting the emergence of monoclonal antibodies, oral Janus Kinase (JAK) inhibitors, and topical non-steroidal drugs into dermatology practices.

Lawrence F. Eichenfield, MD, chief of pediatric and adolescent dermatology at Rady Children's Hospital-San Diego and professor of dermatology and pediatrics at the UC San Diego School of Medicine, was 1 such presenter. Eichenfield spoke in an interview with 

“My duty was to go through some of the topical treatments, and that's been a remarkably rapidly changing place,” Eichenfield explained. “I went through what I called our sort of new, younger non-steroids and our more senior non-steroid topicals.”

Throughout their session, Eichenfield and his fellow panelists covered advancements in dermatology, focusing on topical drugs and systemic medicines. The updates included the US Food and Drug Administration (FDA) approval of new non-steroidal topicals such as tapinarof and ruxolitinib.

They also touched on the extended approval of ruxolitinib for younger patients. In their talk, the panelists’ discussion also covered the importance of managing topical steroid withdrawal, also known as TSW. The 3 panelists highlighted counseling in atopic dermatitis and systemic treatments for children as young as 6 months with the skin disease.

Eichenfield was asked about future developments in the dermatology field in 2026, including OX40 and IL-13 mediator pathway targets. Alopecia areata and vitiligo were described as continuing to see significant research, with topical ruxolitinib showing promise.

To find out more insights on various dermatologic conditions, view updates to coverage of the 

The quotes included in this video summary were edited for clarity.

Disclosures: Eichenfield previously reported receiving personal fees from Pfizer Inc; grant funding from AbbVie, Arcutis Biotherapeutics, Bausch + Lomb, Castle Biosciences, Dermavant Sciences Inc, Galderma SA, Pfizer Inc, Regeneron, and Sanofi SA and consulting for ASLAN Pharmaceuticals, AbbVie, Almirall, SA, Arcutis Biotherapeutics, Arena Pharmaceuticals Inc, Dermavant Sciences Inc, Galderma SA, Incyte Corporation, LEO Pharma A/S, Eli Lilly and Company, Ortho Dermatologics, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi SA, and UCB; and serving on the board of directors of Forté Pharma.

Eichenfield L, Silverberg J, Chovatiya R. Atopic Dermatitis and Pruritus: Current Concepts and Therapeutics for 2026. Presented at: Maui Derm Hawaii 2026; January 25-29, 2026; Maui, Hawaii.

Gallagher K, Halperin-Goldstein S, Paller AS. New treatments in atopic dermatitis update. Ann Allergy Asthma Immunol. 2025 Nov;135(5):498-510.e10. doi: 10.1016/j.anai.2025.06.020. Epub 2025 Jun 23. PMID: 40562170.

At the Maui Derm Hawaii 2026 conference, Lawrence Eichenfield, MD, spoke about highlights from his talk, ‘Atopic Dermatitis and Pruritus: Current Concepts and Therapeutics for 2026.’

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

Risankizumab therapy provided greater clinical response versus deucravacitinib in adult patients with moderate 

, new data suggest, and safety findings are comparable with the known safety profiles of both drugs.

, with the poster being titled, ‘A Phase 4 Multicenter, Randomized, Open-Label, Efficacy Assessor-Blinded Study of Risankizumab Compared With Deucravacitinib for the Treatment of Adult Patients With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy: 16-Week Results From IMMpactful.’

These data were authored by such investigators as Nina Magnolo, MD, from the University Hospital of Münster Department of Dermatology and Venereology. Magnolo et al highlighted the long-term, immune-driven inflammatory condition as being characterized by erythematous, thickened, and scaly skin plaques. They noted multiple biologic and oral systemic options are available for psoriasis, but selection is complicated by differences in safety and efficacy, especially in the absence of direct comparative research.

Risankizumab was designed as a monoclonal antibody targeting interleukin (IL)-23. Both risankizumab and deucravacitinib, an oral tyrosine kinase 2 inhibitor, are both approved for individuals with moderate-to-severe psoriasis. In Magnolo et al’s study, they sought to directly compare the efficacy and safety of risankizumab versus deucravacitinib in adults with moderate disease who had not previously been given biologics.

IMMpactful, a global, phase 4 study, used a randomized, open-label, active-comparator study design. The analysis involved a blinded efficacy assessment (NCT06333860) of these 2 therapies, and those deemed eligible to take part were at least 18 years of age, biologic naïve, and candidates for systemic options. Additionally, they showed body surface area involvement between 10% - 15%, a Psoriasis Area and Severity Index (PASI) score of 12 or more, and a static Physician Global Assessment (sPGA) score of 3. There were 2 phases and the study lasted 52 weeks.

In period A (weeks 0–16), those taking part as subjects were randomized in a 1:2 ratio to be treated either with subcutaneous risankizumab 150 mg at baseline and Week 4 or oral deucravacitinib 6 mg once-per-day. During period B, from Weeks 16 - 52, subjects initially assigned to the deucravacitinib arm continued use every 12 weeks, while those initially on deucravacitinib were re-randomized 1:1 to either switch to risankizumab or continue with deucravacitinib. Stratification was based on PASI 90 response status at the 16-week mark.

Magnolo and colleagues’ co-primary endpoints in period A were the proportion of individuals attaining at least a 90% improvement in PASI (PASI 90) and the proportion attaining an sPGA score of 0 or 1 with a minimum 2-grade improvement from the point of baseline at 16 weeks. Among their key ranked secondary endpoints, they looked at PASI 100 and achievement of sPGA 0 with a 2-grade improvement. The team addressed missing information via non-responder imputation with multiple imputation methods. Only results from period A were reported.

There were 393 enrolled participants. 131 subjects, all of whom had a mean age of 47.3 years, were randomized to risankizumab. 262 individuals with a mean age of 44.8 years were assigned to deucravacitinib. Magnolo et al described baseline disease severity and demographic data as comparable between cohorts. At the 16-week mark, risankizumab demonstrated significantly superior efficacy versus deucravacitinib. There were higher rates of PASI 90 (57.3% versus 22.9%, 

 < .0001), sPGA 0/1 (80.2% versus 39.7%, 

 < .0001), and sPGA 0 (27.5% versus 6.9%, 

Occurrences of treatment-emergent adverse events appeared in 33.6% of those on risankizumab and 42.9% of those on deucravacitinib. The investigative team noted study drug–related adverse events (AEs) in 6.1% and 15.3% of participants, respectively. There was a single serious AE, a joint injury in a patient treated with risankizumab, which was reported and considered unrelated to study medication. A lack of deaths during the study period was also highlighted,

Overall, the study suggests risankizumab therapy produced more robust clinical responses than deucravacitinib in biologic-naïve adults with moderate psoriasis.

Magnolo N, Soung J, Warren R, et al. A Phase 4 Multicenter, Randomized, Open-Label, Efficacy Assessor-Blinded Study of Risankizumab Compared With Deucravacitinib for the Treatment of Adult Patients With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy: 16-Week Results From IMMpactful. Presented at: Maui Derm Hawaii 2026; January 25-29, 2026; Maui, Hawaii.

Armstrong AW, Soliman AM, Gisondi P, Fang S, Patel M, Strober B. Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis. Dermatol Ther (Heidelb). 2024 Oct 25. doi: 10.1007/s13555-024-01293-y. Epub ahead of print. PMID: 39453596.

Articles

In a recent study, risankizumab demonstrated superior efficacy compared to deucravacitinib in treating biologic-naïve adults with moderate psoriasis. Conducted as a phase 4, open-label, randomized trial, the study assessed clinical responses over 16 weeks. Risankizumab showed higher rates of PASI 90, sPGA 0/1, PASI 100, and sPGA 0 improvements. Safety profiles were consistent with known data, with fewer treatment-emergent adverse events reported for risankizumab. The study underscores risankizumab's potential as a more effective treatment option for moderate psoriasis.

The safety and efficacy of risankizumab versus deucravacitinib were evaluated among patients with moderate psoriasis and no prior biologic use.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

IMMpactful: Risankizumab Shows Greater Clinical Response to Deucravacitinib in Psoriasis

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

The US Centers for Medicare & Medicaid Services (CMS) has announced the selection of 15 high-cost prescription drugs covered under Medicare Part D and, for the first time, drugs payable under Medicare Part B for the third cycle of the Medicare Drug Price Negotiation Program. CMS additionally selected 1 previously negotiated drug, linagliptin (Tradjenta), for the program’s first renegotiations.

Under this program, CMS directly negotiates the prices of certain high expenditure, single source drugs without generic or biosimilar competition. As described in a January 27, 2026, release, negotiations with participating drug companies will occur in 2026 and any negotiated and renegotiated prices will become effective January 1, 2028.

“For too long, seniors and taxpayers have paid the price for skyrocketing prescription drug costs,” CMS Administrator Mehmet Oz, MD, MBA, said in a statement. “Under President Trump’s leadership, CMS is taking strong action to target the most expensive drugs in Medicare, negotiate fair prices, and make sure the system works for patients—not special interests. This approach delivers real savings while strengthening accountability across the program.”

CMS selected 10 and 15 drugs covered under Medicare Part D for the first and second cycle of negotiations, respectively, that now have negotiated prices, which the statute refers to as maximum fair prices. These prices are effective beginning January 1, 2026 for the first cycle and January 1, 2027 for the second cycle, based on negotiations and agreements reached between CMS and participating drug companies.

CMS announced the selection of the below list of 15 drugs payable under Medicare Part B and/or covered under Medicare Part D for the third cycle of negotiations, with an initial price applicability year 2028:

Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy)

In the second cycle of negotiations, Medicare reached agreement with participating manufacturers on all 15 selected drugs, with those prices set to take effect on January 1, 2027. Had those new prices been in effect in 2024, they would have saved an estimated $8.5 billion in net covered prescription drug costs (inclusive of Coverage Gap Discount Program Spending), which would have amounted to approximately 36% reduced net spending in aggregate.

Between November 2024 and October 2025, approximately 1.8 million people with Medicare Part D or Medicare Part B coverage used the 15 drugs selected for initial negotiation to treat a variety of conditions, including cancer, psoriatic arthritis, and human immunodeficiency virus type 1 infection. These drugs accounted for approximately $27 billion in total prescription drug spending under Medicare Part B and Part D, representing about 6% of total Part B and Part D spending.

CMS is also releasing a list of 50 top negotiation-eligible drugs based on combined expenditures under Medicare Parts B and D. The drugs selected for the third cycle represent the top 15 highest-spending drugs on this list.

“The publication of the list of top 50 negotiation-eligible drugs evidences CMS’ commitment to transparency,” said CMS Deputy Administrator and Director of Medicare Chris Klomp. “By applying clear eligibility criteria and practical negotiation policies, we are ensuring the program responds to market changes while delivering fairness and value for the American people.”

As described in the release, all drugs were selected in accordance with the final guidance for the third cycle of negotiations, which incorporated refinements based on public feedback to increase the transparency of the Negotiation Program.

Drug companies with a selected drug for the third cycle of negotiations will have until February 28, 2026, to decide if they will participate in negotiations, during which CMS will consider the selected drug’s clinical benefit, evidence about alternative treatments, the extent to which it addresses unmet medical needs, and its impact on specific populations, including people who rely on Medicare. Of note, CMS also considers other information, such as costs associated with research and development as well as current costs of production and distribution for selected drugs.

Centers for Medicare & Medicaid Services. CMS Announces Selection of Drugs for Third Cycle of Medicare Drug Price Negotiation Program, Including First-Ever Part B Drugs. January 27, 2026. Accessed January 29, 2026. 

https://www.cms.gov/newsroom/press-releases/cms-announces-selection-drugs-third-cycle-medicare-drug-price-negotiation-program-including-first

Centers for Medicare & Medicaid Services. Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2028. 

https://www.cms.gov/files/document/factsheet-medicare-negotiation-selected-drug-list-ipay-2028.pdf

The US Centers for Medicare & Medicaid Services (CMS) has selected 15 high-cost drugs for the third cycle of the Medicare Drug Price Negotiation Program, including drugs under Medicare Part B for the first time. This initiative aims to negotiate fair prices for high-expenditure drugs lacking generic or biosimilar competition. The negotiated prices will be effective from January 1, 2028. The program is expected to significantly reduce prescription drug costs, with previous cycles already demonstrating substantial savings. CMS emphasizes transparency and fairness in its negotiation process.

The US Centers for Medicare & Medicaid Services selected 15 high-cost drugs for the third cycle of the Medicare Drug Price Negotiation Program, including the first-ever Part B drugs.

Internal Medicine

Internal Medicine condition center page, resources on the topics of medical news and expert insight into internal medicine can be found. Content includes articles, interviews, videos, podcasts, and breaking news on internal medicine research, treatment, and drug development.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

CMS Selects 15 Drugs for Third Cycle of Medicare Drug Price Negotiation Program

David Bharucha, MD, PhD, is the chief medical officer of Milestone Pharmaceuticals.

Cardamyst (Etripamil) Nasal Spray Now Commercially Available for Adults with PSVT

Milestone Therapeutics’ etripamil nasal spray for the conversion of acute symptomatic episodes of 

paroxysmal supraventricular tachycardia (PSVT)

 to sinus rhythm in adults has officially been released for commercial sale in the US under the brand name Cardamyst.

 on December 12, 2025, Cardamyst is a novel calcium channel blocker nasal spray designed to be self-administered by patients in the event of a PSVT attack, independent of medical oversight. The treatment offers patients a substantial degree of control over what has historically been a difficult-to-predict condition, as well as circumventing the need for hospitalizations and emergency room visits.

“Treatments for PSVT have been quite limited up to this point,” David Bharucha, MD, PhD, chief medical officer of Milestone Pharmaceuticals, told 

 in an exclusive interview. “They’ve been particularly limited for treatments that can be given acutely to patients when they first experience an attack of PSVT. The condition is frequently impinging on patients’ lives because they can’t get through their normal everyday activities, and so acute treatment becomes more critically important.”

Cardamyst’s launch was accompanied by the release of a patient assistance platform, which aims to optimize affordability as Milestone continues to negotiate regarding formulary placement and coverage with insurers. The program includes reimbursement support and copay assistance for the majority of patients with commercial insurance covering Cardamyst. Copays are currently capped at $25.

Cardamyst’s FDA approval was based on several trials within the larger NODE program, including NODE-1, NODE-301 parts 1 and 2, NODE-302, and NODE-303. A collective analysis of these trials was presented at the American Heart Association’s 2025 Scientific Sessions, exhibiting the overall safety, efficacy, and test-dose tolerability of Cardamyst in patients with PSVT.

Across all of the included studies, the Kaplan-Meier estimate of etripamil exposed patients converting to sinus rhythm within 30 minutes (n = 622) was 59.6% (range, 53.6-64.3%), with a recorded mean time to conversion of 18.5 minutes (95% CI, 15.7-21). Additionally, the proportion of patients assigned to placebo across these trials converting to sinus rhythm by 30 minutes ranged from 26.7-34.7%.

The combined analysis also showed the occurrence of primarily mild, transient treatment-emergent adverse events, which primarily took the form of nasal discomfort, nasal congestion, rhinorrhea, throat irritation, and epistaxis. A total of 1107 patients took ≥1 etripamil test dose while in sinus rhythm, and no significant changes in average baseline heart rate or blood pressure was observed within 45 minutes of administration. Test dose failure occurred in only 16 patients (1.4%).

“So, what all this boils down to is that it’s safe and well-tolerated; patients in trials who could take doses for consecutive separated episodes of PSVT attacks returned to this treatment,” Bharucha said. “And the efficacy data demonstrate that it’s fast, effective, and lasts for well beyond 30 minutes. We keyed in on 30 minutes because that was our primary endpoint, and that’s often the time in which patients have to make a decision. In reality, the effects were long-lasting up until 5 hours, which is when we stopped measuring.”

Editor’s Note: Bharucha reports that he is an employee of Milestone Pharmaceuticals.

Milestone Pharmaceuticals. Milestone Pharmaceuticals Announces US Availability of CARDAMYST (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT). January 26, 2026. Accessed January 29, 2026. 

https://investors.milestonepharma.com/news-releases/news-release-details/milestone-pharmaceuticals-announces-us-availability-cardamysttm

Livingston R. FDA Approves Etripamil (Cardamyst) Nasal Spray for PSVT. 

. December 13, 2025. Accessed January 29, 2026. 

https://www.hcplive.com/view/fda-approves-etripamil-cardamyst-nasal-spray-for-psvt

Ip J, Noseworthy P, Piccini J, et al. Combined Efficacy, Safety, and Test Dose Tolerability of Etripamil for Acute Paroxysmal Supraventricular Tachycardia (PSVT) Across Multiple Clinical Trials. AHA/ASA Journals. November 3, 2025. Accessed December 9, 2025. 

https://www.ahajournals.org/doi/10.1161/circ.152.suppl_3.4366812

Milestone Therapeutics’ novel, self-administered medication for paroxysmal supraventricular tachycardia has released alongside a patient support program.

Arrhythmia

Robert Negrin, MD, is president of the American Society of Hematology and a professor of medicine at Stanford University. 

Robert Negrin discusses ASH initiatives to sustain hematology research, early-career careers, and global clinical programs.


Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

ASH Addresses Funding, Career Development Gaps in Hematology, With President Robert Negrin, MD

Nancy Reau, MD, is Professor of Internal Medicine, Richard B. Capps Chair of Hepatology, Associate Director of Solid Organ Transplantation, and Section Chief of Hepatology at Rush University Medical Center.

Nancy Reau, MD, and Kimberly Brown, MD, discuss the challenges of accurately assessing and addressing alcohol use in patients with MASLD.

Hepatology

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

Recognizing, Treating Alcohol as an Additive Risk Factor in MASLD

Video Series

Hope on the Horizon: The Future of GCA Treatment

Reflecting on Trial Limitations in GCA: Painting a Future for IL-17A Targeting Therapies 

With the acceptance, the FDA has assigned the oral phosphate binder a Prescription Drug User Fee Act target action date of June 29, 2026.

Chronic Kidney Disease

FDA News

FDA Accepts Oxylanthanum Carbonate NDA Resubmission for Hyperphosphatemia in CKD, Dialysis

Patrick Campbell is the editorial director of HCPLive. Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter and/or multimedia specialist with the Pocono Record, Star News Group, and NJ Advance Media. He is the executive producer for multiple HCPLive podcasts, including Diabetes Dialogue, Don't Miss a Beat, Kidney Compass, Medical Ethics Unpacked, The Medical Sisterhood, and Skin of Color Savvy. 


Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

The FDA approval is based on a pair of phase 3 trials, including the larfest and longest safety study of presbyopia eye drops. 

Ophthalmology

Ophthalmology page, resources on the topics of medical news and expert insight into ophthalmic disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on eye disease research, treatment, and drug development.

FDA Approves First Dual-Agent Eye Drop for Near Vision Loss

Dawn Eichenfield, MD, PhD, is a dermatologist at Rady Children's Hospital-San Diego and an assistant clinical professor of dermatology at UC San Diego School of Medicine.

This Q&A interview with Dawn Eichenfield, MD, PhD, highlights notable takeaways from her session at Maui Derm Hawaii titled ‘Pediatric Dermatology 2026.’

Spotlighting Pediatric Dermatology Updates for 2026, With Dawn Eichenfield, MD, PhD

Linda Stein Gold, MD, is a dermatologist at Henry Ford Health. 

This interview with Stein Gold continues her discussion of new and emerging psoriasis therapies in 2026.

Emerging Psoriasis, PsA Drugs and Future Developments in Dermatology, With Linda Stein Gold, MD

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

ASH’s multidisciplinary panel provides a standardized diagnostic pathway emphasizing early laboratory testing and surrogate biopsies.

Hematology

ASH Releases New Clinical Practice Guidelines for Diagnosing AL Amyloidosis

Mazen Noureddin, MD, MHSc, is a professor of medicine and a transplant hepatologist at Houston Methodist and director of the Houston Research Institute.

Noureddin recaps recent progress in MASH therapeutic development and looks ahead to what 2026 and beyond may offer.

Latest News

Staying Up Late Associated With CVD Risk Through Worse LE8 Scores, With Sina Kianersi, PhD

Highlighting Therapeutic Updates for Atopic Dermatitis and Itch, With Lawrence Eichenfield, MD

IMMpactful: Risankizumab Shows Greater Clinical Response to Deucravacitinib in Psoriasis

CMS Selects 15 Drugs for Third Cycle of Medicare Drug Price Negotiation Program

Cardamyst (Etripamil) Nasal Spray Now Commercially Available for Adults with PSVT